Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

CRISPR01:59

CRISPR

60.3K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
60.3K
CRISPR/Cas9 Genome Editing01:28

CRISPR/Cas9 Genome Editing

3.2K
The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...
3.2K
What is Genetic Engineering?00:49

What is Genetic Engineering?

81.9K
Overview
81.9K
RNA Editing02:23

RNA Editing

10.2K
RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
10.2K
In-vitro Mutagenesis01:16

In-vitro Mutagenesis

17.7K
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
17.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunogenic implications of translational readthrough modulate the association of F8 nonsense mutations with inhibitors in Hemophilia A.

Molecular medicine (Cambridge, Mass.)·2026
Same author

Synonymous editing alters ion channel function, favoring prime editing for retinal disease correction.

International journal of biological sciences·2026
Same author

Rational design of a novel engineered factor X with chimeric activation peptide as bypassing agent for hemophilia.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Base editing and nanoparticle transfection of airway cell types essential for treatment of cystic fibrosis.

JCI insight·2026
Same author

Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial results.

Research and practice in thrombosis and haemostasis·2026
Same author

In vivo base editing rescues liver pathophysiology and peroxisome dysfunction in a mouse model of Zellweger spectrum disorder.

Nature biomedical engineering·2026

Related Experiment Video

Updated: Apr 17, 2026

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
09:35

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

15.5K

Gene Editing for Haemophilia-The Next Frontier.

Mirko Pinotti1, Gregory A Newby2,3, Sundar Selvaraj4

  • 1Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Emilia-Romagna, Italy.

Haemophilia : the Official Journal of the World Federation of Hemophilia
|April 16, 2026
PubMed
Summary

Genome editing offers a promising alternative to adeno-associated virus (AAV) gene therapy for hemophilia A and B, potentially enabling durable treatments for children and adults by precisely correcting gene defects.

Keywords:
CRISPRbase editingclinical trialsgene editinghaemophiliasafety

More Related Videos

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
08:32

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

4.6K
Enhanced Genome Editing with Cas9 Ribonucleoprotein in Diverse Cells and Organisms
09:51

Enhanced Genome Editing with Cas9 Ribonucleoprotein in Diverse Cells and Organisms

Published on: May 25, 2018

36.5K

Related Experiment Videos

Last Updated: Apr 17, 2026

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
09:35

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

15.5K
CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
08:32

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

4.6K
Enhanced Genome Editing with Cas9 Ribonucleoprotein in Diverse Cells and Organisms
09:51

Enhanced Genome Editing with Cas9 Ribonucleoprotein in Diverse Cells and Organisms

Published on: May 25, 2018

36.5K

Area of Science:

  • * Molecular biology and genetic engineering applied to hematology.
  • * Gene therapy and regenerative medicine for inherited bleeding disorders.

Background:

  • * Current adeno-associated virus (AAV) gene therapies for hemophilia show promise but have limitations like transgene expression loss and adult applicability.
  • * Genome editing technologies offer potential for precise gene correction and targeted transgene insertion, applicable even in neonates.

Purpose of the Study:

  • * To review the advancements and potential of genome editing technologies for treating hemophilia A and B.
  • * To compare genome editing strategies with existing AAV gene therapies.
  • * To highlight the translational potential and challenges of gene editing for hemophilia.

Main Methods:

  • * Exploration of Zinc-Finger nucleases (ZFN) and CRISPR-Cas9 for in vivo targeted gene insertion via homologous directed repair (HDR).
  • * Investigation of base and prime editors for precise gene correction in cellular models.
  • * Review of preclinical and early-phase clinical trial data for gene editing therapies.

Main Results:

  • * Preclinical data show targeted gene insertion of F8/F9 sequences using CRISPR-Cas9 can provide durable hemophilia therapy.
  • * Strategies like using hyperactive FIX Padua and targeting specific loci (e.g., Albumin, CCR5) enhance therapeutic efficiency.
  • * Ex-vivo gene therapy inserting FIX Padua into B lymphocytes has entered clinical trials.

Conclusions:

  • * Genome editing, particularly CRISPR-Cas9, presents a viable strategy for durable hemophilia treatment, potentially overcoming limitations of AAV vectors.
  • * While base and prime editors show promise for specific mutations, their broad applicability is challenged by genetic diversity.
  • * Long-term follow-up and safety monitoring are crucial for the successful clinical translation of gene editing therapies for hemophilia.